English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose: The study was conducted to study the effect of low dose of Mitomycin-C (0.2 mg/ml) as an adjunct for nasolacrimal duct probing to treat adults with primary acquired nasolacrimal duct obstruction and to study the side effects of MMC during probing. Material and methods: It was a prospective, comparative, randomised interventional study. Patients were randomly divided into two groups of 20 each. Cases (20 eyes) with primary acquired NLD obstruction were treated with probing and intraoperative Mitomycin-C and controls (20 eyes) with primary acquired NLD obstruction were treated with only probing. At the end of 4 months, subjective improvement in epiphora and patency on syringing were evaluated. Results: On follow up at 4 months, 35% cases showed mild improvement compared to 25% of controls. Moderate improvement was seen in 10% of cases compared to 5% of controls. Complete improvement was seen in 15% of cases compared to 0% of controls. The overall subjective improvement was seen in 60% of cases compared to 30% of controls. On syringing, NLD was found patent in 15% of cases compared to 5% among controls at 4 months follow up. Conclusion: Our study confirmed the efficacy of probing with MMC in reducing the symptoms of epiphora with fewer side effects in patients with NLDO during 4 months of follow-up.

To study efficacy and safety of probing with Mitomycin-c in adults with primary acquired nasolacrimal duct obstruction